Not all cancers are created equal: Tissue specificity in cancer genes and pathways.

[1]  J. Fernandez-Banet,et al.  The KRASG12C Inhibitor, MRTX849, Provides Insight Toward Therapeutic Susceptibility of KRAS Mutant Cancers in Mouse Models and Patients. , 2019, Cancer discovery.

[2]  S. Sleijfer,et al.  Pan-cancer whole-genome analyses of metastatic solid tumours , 2019, Nature.

[3]  T. Owonikoko,et al.  Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy , 2019, BMC Cancer.

[4]  Samantha Dale Strasser,et al.  Tissue-Specific Oncogenic Activity of KRASA146T. , 2019, Cancer discovery.

[5]  Stephen J. Elledge,et al.  Tissue-specificity in cancer: The rule, not the exception , 2019, Science.

[6]  M. Merad,et al.  Host tissue determinants of tumour immunity , 2019, Nature Reviews Cancer.

[7]  M. Meyerson,et al.  Commensal Microbiota Promote Lung Cancer Development via γδ T Cells , 2019, Cell.

[8]  Jun S. Liu,et al.  Landscape of B cell immunity and related immune evasion in human cancers , 2018, Nature Genetics.

[9]  J. Reader,et al.  Review of Immune Therapies Targeting Ovarian Cancer , 2018, Current Treatment Options in Oncology.

[10]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[11]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[12]  Ville Mustonen,et al.  The repertoire of mutational signatures in human cancer , 2018, Nature.

[13]  J. Kleeff,et al.  Therapeutic developments in pancreatic cancer: current and future perspectives , 2018, Nature Reviews Gastroenterology & Hepatology.

[14]  J. Bluestone,et al.  Immunological Insights Into Liver Metastasis Associated Resistance To Checkpoint Blockade Cancer Immunotherapy , 2018, The Journal of Immunology.

[15]  N. Hacohen,et al.  Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade , 2018, Cell.

[16]  Ashton C. Berger,et al.  Genomic and Functional Approaches to Understanding Cancer Aneuploidy. , 2018, Cancer cell.

[17]  Qikai Xu,et al.  Profound Tissue Specificity in Proliferation Control Underlies Cancer Drivers and Aneuploidy Patterns , 2018, Cell.

[18]  Peter W. Laird,et al.  Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer , 2018, Cell.

[19]  G. Mills,et al.  Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers , 2018, Nature Communications.

[20]  W. Pao,et al.  Tissue-Specific Immunoregulation: A Call for Better Understanding of the "Immunostat" in the Context of Cancer. , 2018, Cancer discovery.

[21]  Steven J. M. Jones,et al.  The Immune Landscape of Cancer , 2018, Immunity.

[22]  Jedd D. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[23]  K. D. de Visser,et al.  Cancer‐Cell‐Intrinsic Mechanisms Shaping the Tumor Immune Landscape , 2018, Immunity.

[24]  Riyue Bao,et al.  The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients , 2018, Science.

[25]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[26]  A. Gonzalez-Perez,et al.  A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations , 2017, Clinical Cancer Research.

[27]  Harini Veeraraghavan,et al.  Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient , 2017, Cell.

[28]  S. Roy,et al.  Microbes and Cancer. , 2017, Annual review of immunology.

[29]  J. Taube,et al.  Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC , 2017, Cancer Immunology Research.

[30]  Adam A. Margolin,et al.  Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. , 2017, Cell reports.

[31]  Chao Cheng,et al.  Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment. , 2017, Cancer research.

[32]  Roland Rad,et al.  Tissue-specific tumorigenesis: context matters , 2017, Nature Reviews Cancer.

[33]  S. Elledge,et al.  Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.

[34]  D. Voehringer,et al.  Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response , 2017, Science Immunology.

[35]  J. Luke,et al.  Density of immunogenic antigens does not explain the presence or absence of the T-cell–inflamed tumor microenvironment in melanoma , 2016, Proceedings of the National Academy of Sciences.

[36]  Hans Clevers,et al.  Tissue-specific mutation accumulation in human adult stem cells during life , 2016, Nature.

[37]  Jun S. Liu,et al.  Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.

[38]  N. McGovern,et al.  A High-Dimensional Atlas of Human T Cell Diversity Reveals Tissue-Specific Trafficking and Cytokine Signatures. , 2016, Immunity.

[39]  J. Visvader,et al.  Persistent Activation of NF-κB in BRCA1-Deficient Mammary Progenitors Drives Aberrant Proliferation and Accumulation of DNA Damage. , 2016, Cell stem cell.

[40]  J. Visvader,et al.  RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers , 2016, Nature Medicine.

[41]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[42]  Jun S. Liu,et al.  Landscape of tumor-infiltrating T cell repertoire of human cancers , 2016, Nature Genetics.

[43]  Martin H. Schaefer,et al.  Cell type-specific properties and environment shape tissue specificity of cancer genes , 2016, Scientific Reports.

[44]  I. Melero,et al.  Evolving synergistic combinations of targeted immunotherapies to combat cancer , 2015, Nature Reviews Cancer.

[45]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[46]  A. Richardson,et al.  Haploinsufficiency for BRCA1 leads to cell-type-specific genomic instability and premature senescence , 2015, Nature Communications.

[47]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[48]  Paz Polak,et al.  Cell-of-origin chromatin organization shapes the mutational landscape of cancer , 2015, Nature.

[49]  N. Hacohen,et al.  Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity , 2015, Cell.

[50]  F. Dietlein,et al.  Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. , 2014, Trends in genetics : TIG.

[51]  M. Salto‐Tellez,et al.  BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. , 2014, Cancer research.

[52]  D. Cescon,et al.  Estrogen controls the survival of BRCA1-deficient cells via a PI3K–NRF2-regulated pathway , 2014, Proceedings of the National Academy of Sciences.

[53]  S. Elledge,et al.  Cumulative Haploinsufficiency and Triplosensitivity Drive Aneuploidy Patterns and Shape the Cancer Genome , 2013, Cell.

[54]  Gary D Bader,et al.  Comprehensive identification of mutational cancer driver genes across 12 tumor types , 2013, Scientific Reports.

[55]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[56]  J. Blayney,et al.  BRCA1 is a key regulator of breast differentiation through activation of Notch signalling with implications for anti-endocrine treatment of breast cancers , 2013, Nucleic acids research.

[57]  Steven J. M. Jones,et al.  Integrated genomic characterization of endometrial carcinoma , 2013, Nature.

[58]  M. Sykes,et al.  Distribution and compartmentalization of human circulating and tissue-resident memory T cell subsets. , 2013, Immunity.

[59]  R. Bernards,et al.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR , 2012, Nature.

[60]  E. Lander,et al.  Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. , 2011, Cell stem cell.

[61]  E. Passegué,et al.  DNA-damage response in tissue-specific and cancer stem cells. , 2011, Cell stem cell.

[62]  Francisco S. Roque,et al.  A large-scale analysis of tissue-specific pathology and gene expression of human disease genes and complexes , 2008, Proceedings of the National Academy of Sciences.

[63]  S. Merajver,et al.  BRCA1 regulates human mammary stem/progenitor cell fate , 2008, Proceedings of the National Academy of Sciences.

[64]  S. Furuta,et al.  Depletion of BRCA1 impairs differentiation but enhances proliferation of mammary epithelial cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[65]  S. Elledge,et al.  The BRCA1 suppressor hypothesis: an explanation for the tissue-specific tumor development in BRCA1 patients. , 2002, Cancer cell.

[66]  Ton N Schumacher,et al.  Cancer Neoantigens. , 2019, Annual review of immunology.

[67]  Li Ding,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations (vol 173, 371.e1, 2018) , 2018 .